Drug Discovery

Takeda proposes to buy cell therapy firm TiGenix for EUR520m

Takeda Pharmaceutical has offered to acquire Belgium-based cell therapy company TiGenix for €520m to expand its late-stage gastroenterology pipeline and its footprint in the US specialty care market.

Sangamo, Pfizer collaborate to develop zinc finger protein gene therapy for ALS

Sangamo Therapeutics and Pfizer have collaborated for the development of a potential gene therapy using zinc finger protein transcription factors (ZFP-TFs) to treat amyotrophic lateral sclerosis (ALS) and frontotemporal lobar degeneration (FTLD) linked to mutations of the C9ORF72 gene.

NovaQuest Capital to buy Viamet Pharmaceuticals

NovaQuest Capital Management has agreed to acquire Viamet Pharmaceuticals, including its product candidate, VT-1161, which has completed Phase 2b clinical trials for the treatment of recurrent vulvovaginal candidiasis (RVVC) and onychomycosis, or fungal nail infection.

Mylan launches Estrace Cream generic after FDA approval

Mylan has launched Estradiol Vaginal Cream USP, 0.01%, the first generic version of Allergan's Estrace Cream, in the US.

Summit signs deal with Eurofarma for Latin American rights to Ridinilazole

Summit Therapeutics has entered into an exclusive licence and commercialization agreement with Eurofarma Laboratórios, granting rights in Latin America to Summit's precision antibiotic ridinilazole in development for the treatment of CDI.

vTv grants GLP-1r agonist diabetes program rights in China to Hangzhou Zhongmei

vTv Therapeutics has entered into a licensing agreement with Hangzhou Zhongmei Huadong Pharmaceutical for rights to develop and commercialize the former’s GLP-1r agonist program in China and other Pacific Rim countries.

MilliporeSigma signs commercial supply agreement with bluebird bio for viral vector manufacturing

MilliporeSigma has signed a commercial supply agreement to manufacture viral vectors for bluebird bio for use in potentially transformative gene therapies.

Cancer Research UK, Celgene to collaborate on new anti-cancer treatments

Cancer Research Technology (CRT), a subsidiary of Cancer Research UK, has entered into collaboration with American biopharmaceutical firm Celgene for the discovery, development and commercialization of new anti-cancer treatments.

Asklepios BioPharmaceutical launches new portfolio company Actus Therapeutics

Asklepios BioPharmaceutical has formed Actus Therapeutics, a new portfolio company based on AskBio’s industry-leading gene therapy platform.